Abstract
A series of chiral linear and macrocyclic bridged pyridines (1-8) has been prepared starting from pyridine-2,6-dicarbonyl dichloride and they screened as antimicrobial agents before. Screening of the compounds for their Inhibition of type A and type B monoamine oxidase activities in mitochondria preparation revealed that the tested compounds showed selective inhibition of type A monoamine oxidase activities in the following order 4a, 6, 5a, 3, 4b, 5b, 1, 4c, 7, 8 and 2, this confirmed by the in vivo tryptamine seizure potentiation model in rats. The tested compounds showed in vivo good pharmacokinetic and pharmacodynamic profiles.